Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.

Qiuying Selina LiuNour Ali Ass'adCecilia Y Arana Yi

Published in: Clinical case reports (2021)

Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.

Keyphrases

chronic myeloid leukemia
interstitial lung disease
systemic sclerosis
rheumatoid arthritis
idiopathic pulmonary fibrosis
pulmonary hypertension